AdaptVac partners with BioConnection to manufacture their COVID-19 vaccine

BioConnection announces that it is collaborating with AdaptVac for the Drug Product manufacture of their COVID-19 vaccine in its state-of-the-art-GMP manufacturing facility in the Netherlands. AdaptVac aims to accelerate the development of safe and efficacious therapeutic and prophylactic vaccines to treat and prevent specific cancers, infectious diseases, and immunological disorders. AdaptVac with its capsid Virus-Like Particle (cVLP) technology could provide a solution to protect against new Covid-19 infections in the still evolving pandemic. Read the full press release here.